Who asks about DSIP and the sleep questions behind it
A near-50-year-old sleep peptide with a great name and surprisingly thin human evidence.
TL;DR
DSIP (delta sleep-inducing peptide) is a small molecule named for deep-sleep effects seen in 1970s animal studies. Human evidence is thin and mixed. It is not FDA-approved. FDA removed it from Category 2 on April 22, 2026, and it is not on the 503A bulks list. People ask about it mainly because sleep problems are so common.
Who asks about DSIP
People who ask about DSIP are usually tired, curious, and out of easy answers. They have often tried the basics — better sleep habits, less caffeine, melatonin — and are scanning for something new. The search is driven by a real problem: restless nights that ordinary fixes have not solved.
What it is
DSIP is short for delta sleep-inducing peptide (in plain English: a tiny protein fragment first linked to deep sleep). It is a chain of nine amino acids, the building blocks of proteins. Researchers isolated it in the late 1970s from rabbit cerebral venous blood, the blood leaving the brain. The name captures a hope more than a proven job, because its true function in humans remains unclear.
How it works
Honest answer: no one fully knows. Think of DSIP as a note found in the body's mailroom with no confirmed address. Early studies in rabbits suggested it might nudge the brain toward slow-wave sleep, the deepest, most restorative stage. But it does not behave like a simple sleeping pill, and its signaling pathways in people are still being mapped.
What the research says
The literature is old, small, and inconsistent. DSIP was first isolated and named for inducing delta (deep) sleep in rabbits (Schoenenberger and Monnier, PNAS, 1977). Later human studies were limited and produced mixed results, and a 2006 review called the case for DSIP as a sleep factor poorly documented and still weak (Kovalzon and Strekalova, 2006). So the science is interesting history more than a settled sleep therapy.
What the evidence does not show
A memorable name is not evidence of benefit or safety. DSIP is not approved, its effects in people are not established, and reliable long-term safety data are missing. Unregulated online sellers are a real risk.
The Halftime POV
We cover DSIP because readers ask, not because it is a proven answer for sleep. For most people, the highest-yield sleep work is unglamorous: consistent timing, light exposure, and ruling out issues like apnea with a physician. We would rather point you there first.
Related reading:
- Sleep quality and aging research
- How sleep deprivation disrupts hormones
- Who asks about longevity
- Why some peptides are still Category 2
FAQ
What is DSIP peptide? DSIP stands for delta sleep-inducing peptide, a small nine-amino-acid molecule first isolated in 1977 from rabbit cerebral venous blood (blood leaving the brain). It was named for its early link to deep, slow-wave sleep in animals. Despite decades of study, its exact role in the human body is still not well understood.
Does DSIP help with sleep? The human evidence is thin and mixed. DSIP was named for sleep effects seen in early animal work, but controlled human trials have been small and inconsistent. There is no reliable proof that DSIP improves sleep in people, and it is not an approved sleep treatment.
Is DSIP FDA-approved? No. DSIP is not FDA-approved for any use. FDA removed DSIP from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, DSIP is not in any FDA 503A category and is not on the 503A bulks list. At its July 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted against recommending emideltide (DSIP) for the Section 503A bulk drug substances list. The committee is advisory, and FDA makes the final decision.
Disclaimer
Several peptides discussed in this article — including DSIP — were previously in FDA's Category 2. FDA removed them from Category 2 on April 22, 2026. As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. This article is educational and is not medical advice.
Sources
- Schoenenberger GA, Monnier M. "Characterization of a delta-electroencephalogram (sleep)-inducing peptide." Proceedings of the National Academy of Sciences, 1977. https://pubmed.ncbi.nlm.nih.gov/265572/
- Kovalzon VM, Strekalova TV. "Delta sleep-inducing peptide (DSIP): a still unresolved riddle." Journal of Neurochemistry, 2006. PubMed 16539679.
- U.S. Food and Drug Administration. "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A." FDA, 2023.
Frequently asked questions
What is DSIP peptide?
DSIP stands for delta sleep-inducing peptide, a small nine-amino-acid molecule first isolated in 1977 from rabbit cerebral venous blood (blood leaving the brain). It was named for its early link to deep, slow-wave sleep in animals. Despite decades of study, its exact role in the human body is still not well understood.
Does DSIP help with sleep?
The human evidence is thin and mixed. DSIP was named for sleep effects seen in early animal work, but controlled human trials have been small and inconsistent. There is no reliable proof that DSIP improves sleep in people, and it is not an approved sleep treatment.
Is DSIP FDA-approved?
No. DSIP is not FDA-approved for any use. FDA removed DSIP from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, DSIP is not in any FDA 503A category and is not on the 503A bulks list. At its July 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted against recommending emideltide (DSIP) for the Section 503A bulk drug substances list. The committee is advisory, and FDA makes the final decision.
Why do people still ask about DSIP?
Poor sleep is common and frustrating, so people search widely for options. DSIP has an intriguing name and a long research history, which keeps it circulating in longevity and biohacking discussions even though solid human data is lacking.
